Abstract
Background
Interferon (IFN)-α and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting.
Objectives
The aim of this study was to determine the relationships between ribavirin exposure and haemoglobin time-course, the time-to-anaemia and the covariates influencing these relationships in a population of patients treated for chronic hepatitis C. In addition, we also intended to establish a simple rule defining the need for dosage adjustment, using data obtained during the first month of treatment.
Methods
A retrospective analysis of 99 patients treated with IFNα plus ribavirin, with known dosage administration history, liver biopsy, demographic data, red blood cell counts, haemoglobin level (1037 measurements, median 10 per patient, range 2–31) and serum Creatinine during the entire treatment period (178 days, range 53–382 days) was conducted. The data were analysed by a pharmacokinetic/pharmacodynamic population model and Weibull time-to-anaemia model. The rule defining the need for dosage adjustment was as follows: adjustment was needed if haemoglobin at steady state (Hss), estimated by the Bayesian method based on data obtained during the first month of treatment, was <12 g/dL for men or <11 g/dL for women.
Results
In both models, anaemia was related to the exposure of erythrocytes to ribavirin at time t (RT in mg/kg/day) by a maximum effect model, with RT50 (dosage administration rate at which half the maximal effect is reached) approximately 12 mg/kg/day, and the significant covariates were initial haemoglobin level and bodyweight. Performances of a Bayesian prediction of Hss based on two early haemoglobin level measurements were encouraging (mean prediction error 0.12 g/dL, precision 0.85 g/dL). The proposed rule for the need of dosage adjustment was able to predict the actual evolution of the dosage regimen in 76% of non-adapted patients and 69% of adapted patients.
Conclusion
The current guidelines for ribavirin dosage administration, based on bodyweight, are adequate, at least in the 45–105kg range. Results indicate that Bayesian therapeutic monitoring could be helpful in controlling ribavirin-induced anaemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Poynard T, Marcellin P, Lee S, et al. Randomized trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32
McHutchinson J, Gordon S, Schiff E, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92
Davis G, Esteban Mur R, Rustgi V, et al. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493–9
Cheng S, Bonis P, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 321–40
Jarvis S, Thorn J, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998; 123: 1587–92
Lertora JJL, Rege AB, Lacour JT, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50: 442–9
Canonico PG, Kastello MD, Spears CT, et al. Effect of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74: 155–62
De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997–1004
Van Vlierberghe H, Delanghe JR, De Vos M, et al. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 911–6
Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555–65
Jen JF, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 349–61
Laskin OL, Longstreth JA, Hart CC, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 41: 546–55
Paroni R, Del Puppo M, Borghi C, et al. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite l,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 1989; 27: 302–7
Beal SL, Sheiner LB. NONMEM users guides. San Francisco (CA): University of California, 1992
Maitre PO, Bührer M, Thomson D, et al. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377–84
White DB, Walavander CA, Liu DY, et al. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. J Pharmacokinet Biopharm 1992; 20: 295–313
Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171–92
Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344–8
Bruchfeld A, Lindahl K, Schvarcz R, et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24(6): 701–8
Jain AB, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8(11): 1007–13
Jacqmin P, Gieschke R, Jordan P, et al. Modeling drug induced changes in biomarkers without using drug concentrations: introducing the K/PD model [abstract]. 10th Population Approach Group in Europe Meeting; 2001 Jun 7–8; Basel
Roberts RB, Laskin OL, Laurence J, et al. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 42: 365–73
Congdon P. Life table and survival analysis. In: Congdon P. Bayesian statistical modelling. New York: John Wiley & Sons, 2001: 432
Acknowledgements
This work was supported in part by INSERM U481. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tod, M., Farcy-Afif, M., Stocco, J. et al. Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C. Clin Pharmacokinet 44, 417–428 (2005). https://doi.org/10.2165/00003088-200544040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200544040-00006